Idorsia Partners With Jamjoom Pharma To Bring QUVIVIQ Insomnia Treatment To Saudi Arabia And The Levant

Idorsia Ltd has entered into an exclusive agreement with Jamjoom Pharmaceuticals Factory Co. (Jamjoom Pharma) to distribute and commercialise QUVIVIQ™ (daridorexant), its innovative treatment for adults with insomnia, across Saudi Arabia and the Levant region. The partnership represents another important step in Idorsia’s global expansion strategy, with the goal of making QUVIVIQ available to more patients in regions where there is a growing demand for effective insomnia treatments.

Benjamin Limal, President of Europe & International Markets at Idorsia, expressed confidence in the partnership, highlighting Jamjoom Pharma’s strong presence in Saudi Arabia and the Levant. He noted that the company’s extensive regulatory knowledge, well-developed commercial infrastructure, and established market position make it an ideal partner to support the successful introduction of QUVIVIQ in the region. He further stated that collaborations such as this are central to Idorsia’s international growth strategy, helping the company expand the commercial reach of QUVIVIQ while improving patient access to innovative sleep therapies worldwide.

Tarek Hosni, Chief Executive Officer of Jamjoom Pharma, said the collaboration reflects the company’s commitment to improving access to advanced healthcare solutions for patients with unmet medical needs. He explained that Jamjoom Pharma will leverage its broad commercial capabilities, market access expertise, and strong regional footprint to ensure the successful launch and availability of QUVIVIQ throughout Saudi Arabia and the Levant. According to him, the partnership will enable more adults suffering from insomnia to benefit from an innovative treatment designed to improve both sleep quality and overall daily functioning.

Under the terms of the agreement, Idorsia will receive an upfront payment and will also be eligible for additional milestone-based payments, along with royalties generated from future net sales of QUVIVIQ. Jamjoom Pharma will hold the marketing authorisation for the product in Saudi Arabia and will be responsible for obtaining regulatory approvals, managing distribution, leading promotional activities, and overseeing the commercialisation of QUVIVIQ across Saudi Arabia and the Levant region. Idorsia will continue to manufacture and supply the finished drug product for all agreed territories.

QUVIVIQ (daridorexant) is a prescription treatment developed specifically for adults experiencing insomnia. Unlike many conventional sleep medications that may cause next-day drowsiness, dependency, or withdrawal symptoms, QUVIVIQ works through a different mechanism. It belongs to a class of medicines known as dual orexin receptor antagonists (DORAs), which selectively block orexin receptors responsible for promoting wakefulness. By targeting the body's natural sleep-wake regulation system rather than broadly suppressing brain activity, the treatment helps patients fall asleep more easily, stay asleep throughout the night, and wake up with reduced morning sleepiness, supporting better daytime performance.

The effectiveness of daridorexant has been demonstrated in clinical studies published in “The Lancet Neurology”. The trials showed that both the 25 mg and 50 mg doses significantly improved key measures of sleep, including sleep onset, sleep maintenance, and self-reported total sleep time, when compared with placebo. In addition, the 50 mg dose produced a statistically significant improvement in daytime functioning, addressing one of the major concerns experienced by people living with chronic insomnia.

QUVIVIQ is currently marketed by Idorsia in North America and Europe and is also available in several Asia-Pacific and Middle Eastern countries through commercial partnerships. The company has further expanded its international presence through a licensing and supply agreement covering Latin America. The new collaboration with Jamjoom Pharma strengthens Idorsia’s global commercial strategy, extending the reach of QUVIVIQ into additional high-potential markets while supporting broader patient access to an innovative treatment for insomnia.